Witryna1 lut 2024 · While the IMpower 133 trial was a trial investigating the combination of an immunotherapy atezolizumab together with chemotherapy in untreated patients with metastatic small cell lung cancer. In the trial, significant improvement of overall survival and progression-free survival in favor of the immunotherapy-containing regimen was … Witrynaesmo.org IMpower130: efficacy and safety from a randomised phase 3 study of carboplatin and nab-paclitaxel with or without atezolizumab in 1L advanced non …
PRzegląd bieżącego Piśmiennictwa - VIA MEDICA
Witryna1 paź 2024 · IMpower133 (NCT02763579), a global phase I/III, double-blind, randomized, placebo-controlled trial, showed that adding atezo (anti–PD-L1) to 1L carboplatin + … WitrynaIMpower132 explored the safety and efficacy of atezolizumab plus pemetrexed and platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung … dark scythe bee swarm
IMpower133 Study Met Co-primary Endpoints at 1st Interim …
Witryna11 kwi 2024 · 李敏教授从广泛期SCLC免疫治疗的现状和挑战、SCLC免疫治疗最佳获益人群的探索和困境以及多角度探索SCLC免疫治疗的优化策略三大重点展开论述。. 近三十年来,SCLC——尤其是广泛期SCLC诊疗最重要的进展即免疫治疗,IMpower133、CASPIAN研究奠定了免疫治疗作为广泛 ... Witryna28 maj 2024 · The Atezo+Chemo patients in the real-world cohort compared with the IMpower 133 trial (n = 201) were older (median age 68 vs. 64 years) and included fewer males (45% vs. 64%), fewer white race (73% vs. 81%), more patients with brain metastases at baseline (23% vs. 9%), and more patients with worse ECOG (2/3) … Witryna1 paź 2024 · IMpower 133 was a double-blind phase III study in which 403 patients with untreated, extensive-stage SCLC patients and an Eastern Cooperative Oncology Group performance status of 0 - 1 were randomized 1:1 to atezolizumab along with carboplatin-etoposide (n = 201) or chemotherapy plus placebo (n = 202). dark scythe roblox